For instance, Hombach and colleagues demonstrated that co-administration of mesenchymal stem cells (MSCs) genetically engineered to secrete IL-7 and IL-12 significantly improved the anti-tumor activity of CEA-targeted CAR T cells in a preclinical model of colon cancer (50). Here, IL7 is linked to neoplasm.